Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis

• Status: Completed
• Trial end date: 1994-09-01
• Target enrollment: 0
• Participant gender: All

Summary

To determine whether deferoxamine prevented the complications of transfusional iron overload.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
• Treatments: Deferoxamine

Criteria

Males and females, 5 years or older, with transfusional hemochromatosis.